8.75

0.34% +0.03

AVITA Medical Inc (RCEL)

Overview News Price History Option Chain Financials Why RCEL Down? Discussions Forecast Stock Split

AVITA Medical Inc stock is currently priced at $8.75, with a 24-hour trading volume of 141.21K. It has seen a +0.34% increased in the last 24 hours and a -42.21% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $8.80 pivot point. If it approaches the $8.52 support level, significant changes may occur.

Previous Close:

$8.72

Open:

$8.94

24h Volume:

141.21K

Market Cap:

$225.75M

Revenue:

$50.14M

Net Income/Loss:

$-35.38M

P/E Ratio:

-7.1721

EPS:

-1.22

Net Cash Flow:

$-39.46M

1W Performance:

+2.70%

1M Performance:

-42.21%

6M Performance:

-18.22%

1Y Performance:

-47.35%

1D Range:

$8.66

$9.1111

52W Range:

$8.01

$21.70

AVITA Medical Inc Stock (RCEL) Company Profile

Name

AVITA Medical Inc

Sector

Healthcare (1213)

Industry

Medical Devices (160)

Phone

833 462 8482

Address

28159 Avenue Stanford, Suite 220, Valencia, CA

Employee

Twitter

@AvitaMedical

Next Earnings Date

2024-05-13

Latest SEC Filings

RCEL's Discussions on Twitter

AVITA Medical Inc Stock (RCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-27-23	Initiated	Cantor Fitzgerald	Overweight
Mar-02-21	Initiated	Piper Sandler	Overweight
Aug-27-20	Initiated	BofA Securities	Buy
Apr-21-20	Initiated	Oppenheimer	Outperform
Mar-03-20	Initiated	BTIG Research	Buy

AVITA Medical Inc Stock (RCEL) Latest News

AVITA Medical to Announce First Quarter 2024 Financial Results

GlobeNewswire Inc.

Nasdaq Jumps 250 Points; Crude Oil Down 1%

Benzinga

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Dow Dips 100 Points; CarMax Earnings Miss Views

Benzinga

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Benzinga

AVITA Medical Inc Stock (RCEL) Financials Data

AVITA Medical Inc (RCEL) Revenue 2024

RCEL reported a revenue (TTM) of $50.14 million for the quarter ending December 31, 2023, a +45.68% rise year-over-year.

AVITA Medical Inc (RCEL) Net Income 2024

RCEL net income (TTM) was -$35.38 million for the quarter ending December 31, 2023, a -32.69% decrease year-over-year.

AVITA Medical Inc (RCEL) Cash Flow 2024

RCEL recorded a free cash flow (TTM) of -$39.46 million for the quarter ending December 31, 2023, a -101.16% decrease year-over-year.

AVITA Medical Inc (RCEL) Earnings per Share 2024

RCEL earnings per share (TTM) was -$1.40 for the quarter ending December 31, 2023, a -30.84% decline year-over-year.

AVITA Medical Inc Stock (RCEL) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
CORBETT JAMES	CEO	Dec 26 '23	Sale	13.29	1,445	19,204	11,580
COOK JEREMY CURNOCK	Director	Dec 13 '23	Sale	12.27	2,518	30,896	20,596
O'Toole David D	CFO	Dec 12 '23	Buy	12.45	950	11,828	17,484
O'Toole David D	CFO	Dec 01 '23	Buy	10.68	500	5,340	16,534
O'Toole David D	CFO	Nov 21 '23	Buy	10.28	2,000	20,560	15,000
O'Toole David D	CFO	Nov 16 '23	Buy	12.15	1,000	12,150	12,000
O'Toole David D	CFO	Nov 15 '23	Buy	13.25	1,000	13,250	11,000
O'Toole David D	CFO	Nov 15 '23	Buy	12.45	1,000	12,450	13,000
O'Toole David D	CFO	Nov 14 '23	Buy	12.88	1,000	12,880	10,000
Shiroma Donna	General Counsel	Aug 21 '23	Sale	15.84	4,193	66,417	42,257

AVITA Therapeutics, Inc. operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company has a preclinical research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa. The company is based in Valencia, California.